Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MANE

Veradermics Inc

Apr 27 • 12:31PM ET

94.46

+26.62 39.24 %

Healthcare • Biotechnology • USA • Mid • NYSE

Today, 7:10 AMVeradermics' VDPHL01 Phase 2/3 Part A data show strong hair-growth efficacy, no treatment-related cardiovascular events in male pattern hair loss

Held by: VTI VXF SCHA LFSC ITOT FPX SCHB VTWO BOUT VTWG

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	23.01%	Shs Outstand	37.34M	Perf Week	27.70%
Market Cap	3.53B	Forward P/E	-	EPS next Y	-2.82	Insider Trans	49.49%	Shs Float	28.75M	Perf Month	39.84%
Enterprise Value	3.65B	PEG	-	EPS next Q	-0.65	Inst Own	20.67%	Short Float	6.23%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	24.71%	Inst Trans	15.52%	Short Ratio	4.01	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-6.33%	ROA	-	Short Interest	1.79M	Perf YTD	150.23%
Book/sh	-3.24	P/C	24.86	EPS next 5Y	17.21%	ROE	-	52W High	80.90 16.76%	Perf Year	-
Cash/sh	3.80	P/FCF	-	EPS past 3/5Y	-117.94% -	ROIC	-	52W Low	32.00 195.19%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.93% 9.87%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	7.70	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	16.29	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	72.79	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	16.29	EPS Q/Q	-	SMA20	36.82%	Beta	-	Target Price	95.33
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	60.39%	Rel Volume	10.58	Prev Close	67.84
Employees	21	LT Debt/Eq	0.00	Earnings	Mar 30 BMO	SMA200	67.00%	Avg Volume	446.46K	Price	94.46
IPO	Feb 04, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	41.47% -	Trades		Volume	2,319,115	Change	39.24%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-02-26	Initiated	Leerink Partners	Outperform	$75
Mar-02-26	Initiated	Jefferies	Buy	$75
Mar-02-26	Initiated	Citigroup	Buy	$85
Mar-02-26	Initiated	Cantor Fitzgerald	Overweight

Today 09:52AM	Veradermics Shares Jump 17% on Promising Hair Loss Trial Results (InvestorsHub) +39.24%
09:31AM	How This Biotech, Up 25%, Is Taking A Page Out Of Rogaine's Playbook (Investor's Business Daily)
07:03AM	A new version of an old drug is helping men grow back some of their hair (MarketWatch)
07:00AM	Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 '302' Clinical Trial in Male Pattern Hair Loss (Business Wire)
Apr-26-26 04:00PM	Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 302 Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss (Business Wire)
01:13PM	Loading…
Apr-01-26 01:13PM	Squawk Pod: OpenAI's eye-popping raise & hair today, hair forever - 04/01/26 Audio Only (CNBC TV) -6.92%
Mar-30-26 07:30AM	Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates (Business Wire) -7.14%
Mar-18-26 07:00AM	Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting (Business Wire)
Mar-03-26 07:00AM	Veradermics to Participate in Upcoming March Investor Conferences (Business Wire)
Feb-26-26 08:04PM	Flagship-Backed Generate Biomedicines Raises $400 Million in IPO (Bloomberg) +6.85%
07:39AM	For the first time in decades, new hair-loss treatments are in the works. Heres how theyre different. (MarketWatch)
Feb-25-26 03:36PM	For the first time in decades, new hair-loss treatments are in the works. Here's how they're different. (MarketWatch)
Feb-16-26 08:40AM	Reddit, KKR, and 2 Biotech IPOs Seeing the Love From Insiders (24/7 Wall St.)
Feb-12-26 08:55AM	NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell (PR Newswire)
Feb-09-26 07:30AM	Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss (Business Wire)
04:18PM	Loading…
Feb-06-26 04:18PM	Jennifer Garner's Once Upon a Farm Rises Nearly 20% To Wrap Up Busy Week for IPOs (Barrons.com)
Feb-05-26 04:05PM	Veradermics Announces Closing of Full Exercise of Underwriters Option to Purchase Additional Shares in Initial Public Offering (Business Wire)
Feb-04-26 04:12PM	No Revenue? No Problem. Biotech Targeting Hair Loss Doubles in Stock IPO. (Barrons.com)
01:07PM	This week's first IPO is set for a warm Wall Street welcome (MarketWatch)
08:55AM	NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA (PR Newswire)
Feb-03-26 09:57PM	Veradermics Announces Pricing of Upsized Initial Public Offering (Business Wire)

Veradermics, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company was founded in 2019 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 04 '26	Buy	37.05	155,953	5,778,342	3,648,538	Feb 09 06:28 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 05 '26	Buy	37.99	96,200	3,655,079	489,932	Feb 09 06:28 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 06 '26	Buy	36.34	30,521	1,109,056	520,453	Feb 09 06:28 PM
Coric Vlad	Director	Feb 05 '26	Buy	17.00	117,646	1,999,982	319,398	Feb 05 07:04 PM
CHILDS JOHN W	Director	Feb 05 '26	Buy	17.00	294,117	4,999,989	2,202,006	Feb 05 07:04 PM
Longitude Capital Partners V,	10% Owner	Feb 05 '26	Buy	17.00	1,075,000	18,275,000	2,600,399	Feb 05 07:03 PM
ENRIGHT PATRICK G	Director	Feb 05 '26	Buy	17.00	1,075,000	18,275,000	2,600,399	Feb 05 07:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MANE

Veradermics Inc

Upgrade your Finviz experience